RNA療法の臨床試験市場- 世界の産業規模、シェア、動向、機会、予測、モダリティ別、フェーズ別、治療分野別、地域別、競合別、2020-2030年予測

RNA療法の臨床試験の世界市場規模は2024年に28億7,000万米ドル、2030年には40億1,000万米ドルに達し、予測期間中のCAGRは5.73%で拡大すると予測されています。

RNA治療は、遺伝子発現を標的とすることで、さまざまな疾患を治療する画期的なアプローチを提供する、医学研究の最先端領域です。メッセンジャーRNA（mRNA）、small interfering RNA（siRNA）、アンチセンス・オリゴヌクレオチド（ASO）などのリボ核酸（RNA）分子を活用するRNAベース療法は、遺伝子活性を制御する精密主導型の手法を提供します。このアプローチは、遺伝性疾患、感染症、がん、そして現在有効な治療法がない希少疾患への対応に大きな期待が寄せられています。

従来の医薬品とは異なり、RNA療法は遺伝子レベルで作用するため、より的を絞った個別化治療が可能となります。世界の臨床試験の急増は、RNA科学の進歩と、ヘルスケアの展望を再定義したmRNAワクチンなどのRNAベースの製品開発の成功を反映しています。学術機関、製薬会社、研究機関の協力によって実施されるこれらの臨床試験は、規制当局の承認に先立ってこれらの革新的な治療法の安全性と有効性を評価する上で極めて重要です。

市場促進要因

RNA技術革新の加速

主な市場課題

送達メカニズムの複雑さ

主要市場動向

個別化医療と精密医療の進展

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のRNA療法の臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • モダリティ別（RNA干渉、アンチセンス療法、メッセンジャーRNA、オリゴヌクレオチド、非アンチセンス、非RNAi）
  • フェーズ別（フェーズI、フェーズII、フェーズIII、フェーズIV）
  • 治療領域別（希少疾患、抗感染症、抗がん、神経系、消化器・代謝系、筋骨格系、循環器・呼吸器系、感覚器系、その他）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2024）
• 製品市場マップ
  • モダリティ別
  • フェーズ別
  • 治療領域別
  • 地域別

第6章 北米のRNA療法の臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のRNA療法の臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のRNA療法の臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア

第9章 南米のRNA療法の臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのRNA療法の臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品開発
• 最近の動向

第13章 競合情勢

• IQVIA Inc.
• ICON Plc
• Laboratory Corporation of America Holdings
• Charles River Laboratories International, Inc.
• PAREXEL International Corp.
• Syneos Health
• Medpace Holdings, Inc.
• Novotech Inc.
• PPD Inc.
• Veristat, LLC.

第14章 戦略的提言

第15章 調査会社について・免責事項

Global RNA Therapy Clinical Trials Market was valued at USD 2.87 billion in 2024 and is projected to reach USD 4.01 billion by 2030, expanding at a CAGR of 5.73% during the forecast period.

RNA therapy represents a cutting-edge domain in medical research, offering a transformative approach to treating a wide range of diseases by targeting gene expression. Leveraging ribonucleic acid (RNA) molecules such as messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), RNA-based therapies provide a precision-driven method to regulate gene activity. This approach holds significant promise in addressing genetic disorders, infectious diseases, cancer, and rare conditions that currently lack effective treatment options.

Unlike conventional pharmaceuticals, RNA therapies operate at the genetic level, enabling more targeted and personalized treatment solutions. The surge in clinical trials globally reflects both advancements in RNA science and the successful development of RNA-based products, such as mRNA vaccines, which have redefined the healthcare landscape. These clinical trials, conducted through collaborations between academic institutions, pharmaceutical companies, and research organizations, are pivotal in evaluating the safety and efficacy of these innovative therapies prior to regulatory approval.

Key Market Drivers

Accelerated Innovation in RNA Technology

The market's growth is largely fueled by rapid technological advancements in RNA science, reshaping the future of medicine and therapeutic development. A critical area of progress is the refinement of RNA synthesis techniques, which now enable the creation of highly specific and efficient RNA molecules customized to target particular genes or disease pathways.

For instance, in May 2022, Moderna and the nonprofit research organization IAVI announced the initiation of Phase I clinical trials for an experimental mRNA-based HIV vaccine (mRNA-1644), with initial screenings in Rwanda and South Africa.

Further innovations in RNA modification have enhanced molecular stability, reducing degradation and improving biodistribution, which extends the therapeutic effect and reduces dosing frequency-key factors in improving patient compliance. Delivery technologies have also evolved significantly, with lipid nanoparticles and polymer-based carriers protecting RNA during systemic circulation and facilitating precise cellular uptake.

Additionally, combination RNA therapies-which integrate multiple RNA modalities or pair RNA treatments with other therapeutic strategies-are under exploration, offering synergistic potential for more comprehensive disease management.

Key Market Challenges

Complexities in Delivery Mechanisms

A major challenge within the RNA therapy clinical trials market is the effective delivery of RNA molecules to specific cells or tissues. Due to their inherent fragility, RNA molecules are susceptible to enzymatic degradation and immune system activation, limiting their therapeutic utility if not adequately protected and directed.

Moreover, RNA molecules typically exhibit short biological half-lives, requiring repeated administrations to maintain therapeutic levels. Efficient delivery systems are essential to ensure therapeutic RNA reaches the intended cellular targets while minimizing systemic exposure and off-target effects.

To overcome these barriers, researchers have developed advanced delivery platforms-most notably lipid nanoparticle formulations-that encapsulate RNA, shielding it from degradation and enhancing cellular uptake. These systems can be engineered for targeted delivery, ensuring better therapeutic outcomes and minimizing toxicity.

However, challenges remain, particularly in achieving consistent delivery across varied patient profiles and disease states, making delivery optimization a key area of ongoing research and development.

Key Market Trends

Advancing Personalized and Precision Medicine

The shift toward personalized and precision medicine is a transformative trend shaping the RNA therapy clinical trials landscape. This approach leverages individual genetic and molecular profiles to tailor therapeutic interventions, significantly improving treatment outcomes and minimizing adverse effects.

In RNA therapy, personalized medicine involves designing RNA-based therapies that target patient-specific mutations or gene expressions. This enables highly focused treatment strategies, especially for rare or complex conditions.

Precision medicine goes a step further by using genetic profiling and advanced diagnostics to predict how patients will respond to specific RNA therapies. This data-driven approach enhances treatment efficacy, optimizes resource allocation in clinical trials, and supports the development of more targeted RNA-based drug candidates.

Key Market Players

IQVIA Inc.

ICON Plc

Laboratory Corporation of America Holdings

Charles River Laboratories International, Inc.

PAREXEL International Corp.

Syneos Health

Medpace Holdings, Inc.

Novotech Inc.

PPD Inc.

Veristat, LLC.

Report Scope:

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Therapy Clinical Trials Market, By Modality:

RNA interference

Antisense therapy Messenger RNA

Oligonucleotide

Non-antisense

Non-RNAi

RNA Therapy Clinical Trials Market, By Phase:

Phase I

Phase II

Phase III

Phase IV

RNA Therapy Clinical Trials Market, By Therapeutic Area:

Rare Diseases

Anti-infective

Anticancer

Neurological

Alimentary/Metabolic

Musculoskeletal

Cardiovascular Respiratory

Sensory

Others

RNA Therapy Clinical Trials Market, By Region:

North America

• United States
• Canada
• Mexico

Europe

• Germany
• France
• United Kingdom
• Italy
• Spain

Asia-Pacific

• China
• Japan
• India
• South Korea
• Australia
• Singapore

South America

• Brazil
• Argentina
• Colombia

Middle East & Africa

• UAE
• Saudi Arabia
• South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Types
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global RNA Therapy Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)
  • 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.3. By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Modality
  • 5.3.2. By Phase
  • 5.3.3. By Therapeutic Areas
  • 5.3.4. By Region

6. North America RNA Therapy Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Modality
  • 6.2.2. By Phase
  • 6.2.3. By Therapeutic Areas
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Therapy Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Modality
      • 6.3.1.2.2. By Phase
      • 6.3.1.2.3. By Therapeutic Areas
  • 6.3.2. Canada RNA Therapy Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Modality
      • 6.3.2.2.2. By Phase
      • 6.3.2.2.3. By Therapeutic Areas
  • 6.3.3. Mexico RNA Therapy Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Modality
      • 6.3.3.2.2. By Phase
      • 6.3.3.2.3. By Therapeutic Area

7. Europe RNA Therapy Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Modality
  • 7.2.2. By Phase
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany RNA Therapy Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Modality
      • 7.3.1.2.2. By Phase
      • 7.3.1.2.3. By Therapeutic Area
  • 7.3.2. France RNA Therapy Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Modality
      • 7.3.2.2.2. By Phase
      • 7.3.2.2.3. By Therapeutic Area
  • 7.3.3. United Kingdom RNA Therapy Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Modality
      • 7.3.3.2.2. By Phase
      • 7.3.3.2.3. By Therapeutic Area
  • 7.3.4. Italy RNA Therapy Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Modality
      • 7.3.4.2.2. By Phase
      • 7.3.4.2.3. By Therapeutic Area
  • 7.3.5. Spain RNA Therapy Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Modality
      • 7.3.5.2.2. By Phase
      • 7.3.5.2.3. By Therapeutic Area

8. Asia-Pacific RNA Therapy Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Modality
  • 8.2.2. By Phase
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China RNA Therapy Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Modality
      • 8.3.1.2.2. By Phase
      • 8.3.1.2.3. By Therapeutic Area
  • 8.3.2. Japan RNA Therapy Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Modality
      • 8.3.2.2.2. By Phase
      • 8.3.2.2.3. By Therapeutic Area
  • 8.3.3. India RNA Therapy Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Modality
      • 8.3.3.2.2. By Phase
      • 8.3.3.2.3. By Therapeutic Area
  • 8.3.4. South Korea RNA Therapy Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Modality
      • 8.3.4.2.2. By Phase
      • 8.3.4.2.3. By Therapeutic Area
  • 8.3.5. Australia RNA Therapy Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Modality
      • 8.3.5.2.2. By Phase
      • 8.3.5.2.3. By Therapeutic Area

9. South America RNA Therapy Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Modality
  • 9.2.2. By Phase
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil RNA Therapy Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Modality
      • 9.3.1.2.2. By Phase
      • 9.3.1.2.3. By Therapeutic Area
  • 9.3.2. Argentina RNA Therapy Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Modality
      • 9.3.2.2.2. By Phase
      • 9.3.2.2.3. By Therapeutic Area
  • 9.3.3. Colombia RNA Therapy Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Modality
      • 9.3.3.2.2. By Phase
      • 9.3.3.2.3. By Therapeutic Area

10. Middle East and Africa RNA Therapy Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Modality
  • 10.2.2. By Phase
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE RNA Therapy Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Modality
      • 10.3.1.2.2. By Phase
      • 10.3.1.2.3. By Therapeutic Area
  • 10.3.2. Saudi Arabia RNA Therapy Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Modality
      • 10.3.2.2.2. By Phase
      • 10.3.2.2.3. By Therapeutic Area
  • 10.3.3. South Africa RNA Therapy Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Modality
      • 10.3.3.2.2. By Phase
      • 10.3.3.2.3. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Competitive Landscape

• 13.1. IQVIA Inc.
  • 13.1.1. Business Overview
  • 13.1.2. Company Snapshot
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As Reported)
  • 13.1.5. Recent Developments
  • 13.1.6. Key Personnel Details
  • 13.1.7. SWOT Analysis
• 13.2. ICON Plc
• 13.3. Laboratory Corporation of America Holdings
• 13.4. Charles River Laboratories International, Inc.
• 13.5. PAREXEL International Corp.
• 13.6. Syneos Health
• 13.7. Medpace Holdings, Inc.
• 13.8. Novotech Inc.
• 13.9. PPD Inc.
• 13.10. Veristat, LLC.

14. Strategic Recommendations

15. About Us & Disclaimer